ARI-0003

N/A

Report date: 2025/01/26 16:49:13

Base Information

Drug NameARI-0003
Drug Alias Namedual anti-CD19/anti-BCMA CAR T-cell therapy (Institut d'Investigacions Biomediques/CICbioGUNE/Instituto de Investigación Sanitaria/Hospital Clinic of Barcelona)ARI-0003
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsTumor necrosis factor ligand superfamily member 13 modulators
TargetsB-lymphocyte antigen CD19Tumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInstitut D'Investigacions Biomediques August Pi I Sunyer
China Registration ClassN/A

Develop Information

Active CompaniesInstitut D'Investigacions Biomediques August Pi I SunyerHospital Clinic Of Barcelona (Es)Centro de Investigacion Cooperativa en Biociencias - CIC bioGUNE +[4] 
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A